Showing results (31-40 of 927) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trialsPeter Rossing, Silvio E Inzucchi, Priya Vart, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2021
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trialSubodh Verma, Nitish K Dhingra, Javed Butler, et al.
The Lancet. Diabetes & Endocrinology|December 26, 2021
Subclinical hypothyroidism in older individualsBernadette Biondi, Anne R Cappola
The Lancet. Diabetes & Endocrinology|March 4, 2021
Thyroid cancer incidence trends by histology in 25 countries: a population-based studyAdalberto Miranda-Filho, Joannie Lortet-Tieulent, Freddie Bray, et al.
The Lancet. Diabetes & Endocrinology|March 4, 2021
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trialMatthias von Herrath, Stephen C Bain, Bruce Bode, et al.
The Lancet. Diabetes & Endocrinology|October 2, 2022
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based studyDunya Tomic, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|August 25, 2022
Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based surveyCihan Atila, Paul Benjamin Loughrey, Aoife Garrahy, et al.
The Lancet. Diabetes & Endocrinology|September 16, 2022
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling studyGabriel A Gregory, Thomas I G Robinson, Sarah E Linklater, et al.
The Lancet. Diabetes & Endocrinology|September 24, 2022
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trialHiddo J L Heerspink, Naveed Sattar, Imre Pavo, et al.
The Lancet. Diabetes & Endocrinology|September 11, 2015
Association between hyperglycaemia and adverse perinatal outcomes in south Asian and white British women: analysis of data from the Born in Bradford cohortDiane Farrar, Lesley Fairley, Gillian Santorelli, et al.
Pageof 93